These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 25633241)

  • 1. New treatment paradigms in psoriatic arthritis: an update on new therapeutics approved by the U.S. Food and Drug Administration.
    Felquer ML; Soriano ER
    Curr Opin Rheumatol; 2015 Mar; 27(2):99-106. PubMed ID: 25633241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Certolizumab pegol for the treatment of psoriatic arthritis.
    Hansen RB; Kavanaugh A
    Expert Rev Clin Immunol; 2015 Mar; 11(3):307-18. PubMed ID: 25651776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Certolizumab pegol (Cimzia) and ustekinumab (Stelara) for psoriatic arthritis.
    Med Lett Drugs Ther; 2014 Feb; 56(1435):10-2. PubMed ID: 24662976
    [No Abstract]   [Full Text] [Related]  

  • 4. Profile of certolizumab and its potential in the treatment of psoriatic arthritis.
    Chimenti MS; Saraceno R; Chiricozzi A; Giunta A; Chimenti S; Perricone R
    Drug Des Devel Ther; 2013; 7():339-48. PubMed ID: 23620660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apremilast for the treatment of psoriatic arthritis.
    Varada S; Tintle SJ; Gottlieb AB
    Expert Rev Clin Pharmacol; 2014 May; 7(3):239-50. PubMed ID: 24702658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apremilast for the treatment of psoriatic arthritis.
    Souto A; Gómez-Reino JJ
    Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug safety evaluation of apremilast for treating psoriatic arthritis.
    Busa S; Kavanaugh A
    Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psoriatic arthritis for the dermatologist.
    Tintle SJ; Gottlieb AB
    Dermatol Clin; 2015 Jan; 33(1):127-48. PubMed ID: 25412788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ustekinumab : targeting the IL-17 pathway to improve outcomes in psoriatic arthritis.
    Weitz JE; Ritchlin CT
    Expert Opin Biol Ther; 2014 Apr; 14(4):515-26. PubMed ID: 24555741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation.
    Dressler C; Eisert L; Pham PA; Nast A
    J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1249-1260. PubMed ID: 30735612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.
    Araujo EG; Englbrecht M; Hoepken S; Finzel S; Kampylafka E; Kleyer A; Bayat S; Schoenau V; Hueber A; Rech J; Schett G
    Semin Arthritis Rheum; 2019 Feb; 48(4):632-637. PubMed ID: 30037432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis.
    Mease PJ; Armstrong AW
    Drugs; 2014 Mar; 74(4):423-41. PubMed ID: 24566842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Psoriatic Arthritis: Traditional Disease-Modifying Rheumatic Agents and Targeted Small Molecules.
    Soriano ER
    Rheum Dis Clin North Am; 2015 Nov; 41(4):711-22. PubMed ID: 26476228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current concepts and new developments in the treatment of psoriatic arthritis.
    Pipitone N; Kingsley GH; Manzo A; Scott DL; Pitzalis C
    Rheumatology (Oxford); 2003 Oct; 42(10):1138-48. PubMed ID: 12810935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis.
    Lubrano E; Perrotta FM
    Drugs; 2016 Apr; 76(6):663-73. PubMed ID: 26957495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Certolizumab: efficacy and safety profile of a novel pegylated TNF-alpha blocking agent.
    Lubrano E; Spadaro A
    Acta Biomed; 2011 Apr; 82(1):26-34. PubMed ID: 22069953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ustekinumab for the treatment of psoriatic arthritis.
    Wofford J; Menter A
    Expert Rev Clin Immunol; 2014 Feb; 10(2):189-202. PubMed ID: 24410536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.
    Abdulrahim H; Thistleton S; Adebajo AO; Shaw T; Edwards C; Wells A
    Expert Opin Pharmacother; 2015 May; 16(7):1099-108. PubMed ID: 25864487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.